NIMESULIDE FOR EXTERNAL USE

Abstract: An antiinflammatory agent for external use, containing nimesulide as the active ingredient dispersed in the base component and being well absorbable, safe and discoloration-free.

Description: The present invention relates to an antiinflammatory agent for external use comprising nimesulide as an active ingredient. In particular, the present invention relates to an antiinflammatory agent for external use comprising nimesulide as an active ingredient and a base component wherein the nimesulide is mixed in a dispersed state in the base component, as well as to a process for preparing the same. Non-steroidal antiinflammatory preparations have a disadvantage that, when orally administered, they cause gastrointestinal tract disorders. In order to avoid this disadvantage, various studies have been made to develop antiinflammatory agent for external use and several commercial products have been provided for clinical use. However, the antiinflammatory agent for external use hitherto developed have insufficient clinical effects even if they show effects in the basic tests. Nimesulide (4-nitro-2-phenoxymethanesulfonanilide), which is one of the non-steroidal antiinflammatory agents, was first synthesized by Riker Co. in the United States and then developed as an oral preparation in Europe by Helsinn Co. in Switzerland. Being different from the conventional acidic antiinflammatory agents, it is known that nimesulide selectively inhibits PGE2 (COX2) and this is a new type pharmaceutical agent expected to take effects in clinical use. As the prior art regarding nimesulide, the substance patent described in U.S. Patent No. 3,480,597 and process patents described in the examined Japanese patent publication ( Kokoku ) Sho-58-35989, the examined Japanese patent publication ( Kokoku ) Sho-58-50984 and the examined Japanese patent publication ( Kokoku ) Sho-59-44311 may be cited. However, these prior art references do not have descriptions or working examples regarding the actual pharmaceutical preparations, although they mention dosage forms such as capsule, cream, gel, tape, and the like. In addition, the laid-open Japanese patent application ( Kohyo ) Hei-6-502842 based on the international patent application may be cited as a reference relating to the pharmaceutical preparation of nimesulide. This patent is to prepare an inclusion compound of nimesulide with cyclodextrin to make nimesulide water-soluble so as to increase water-solubility and to increase absorption of nimesulide in the gastrointestinal tract. Therefore; its object is not the external use. WO-A-93/01836 discloses topical formulations of poorly water-soluble or insoluble drugs, particularly steroids or non steroidic antiinflammatory drugs, having a water content not higher than about 40%. Thus, no reference is known which illustratively discloses use of nimesulide as an external preparation, and no case is known with respect to the actual external use of nimesulide in a particular dosage form. It would be due to the fact that, although nimesulide has pharmacological effects equal to or higher than those of indomethacin which is regarded as a potent antiinflammatory agent, it has several unsolved problems when topically applied as an external preparation. That is, (1) nimesulide is hardly soluble and is not easily dissolved in water and various organic solvents. (2) A solvent which has strong solubilizing ability should be mixed to dissolve nimesulide, causing problems such as skin irritation, chapped skin, itch, and flare. (3) Even if nimesulide is dissolved, the resulting pharmaceutical preparation becomes deep yellow and thus its appearance becomes bad. (4) The pharmaceutical preparation applied soils clothes that contact the preparation. Thus, there is a situation that the attempt to use nimesulide as the external preparation was abandoned. The object of the present invention is to obtain an antiinflammatory agent for external use including nimesulide for topical use, which is a nimesulide external preparation showing excellent absorption and having no problem in coloring and skin safety. As a result of extensive studies taking the above-described disadvantages of nimesulide as an external preparation into consideration, the present inventors found that the above-described disadvantages are all solved by an antiinflammatory agent comprising nimesulide according to claim 1. That is, when nimesulide is formulated as taught in claim 1, it surprisingly shows pharmacological effects equal to or higher than those of the pharmaceutical preparation in which nimesulide is mixed in a dissolved form. In addition, the amount of a solubilizing agent can be reduced and therefore the skin safety is improved. Furthermore, it is proved that the coloring of the pharmaceutical preparation does not occur, which is different from the completely dissolved-type pharmaceutical preparation. That is, all the above-described problems as the external preparation can be solved. Nimesulide as an active ingredient may be used in any form as long as it can be made into a dispersed state in a base component. In view of the easiness in grinding of the particles to be dispersed and the cost, the mean particle diameter of nimesulide is preferably 0.01 µm or more. On the other hand, in view of the transdermal absorbability and feeling on application (rough feeling), it is preferably 75 µm or less, i.e., the particle sizes that pass through a 200-mesh sieve, and more preferably from 0.5 to 50 µm, and further preferably from 1 to 30 µm. The antiinflammatory agent for external use of the present invention may be prepared as follows. For example, the cream agent is prepared by mixing and stirring an oil phase of heat-melted oil components and an aqueous phase in which water-soluble components have been dissolved; adding nimesulide in a form of fine particles; and further carrying out stirring and cooling. The pH of the pharmaceutical preparation may desirably be controlled from 4 to 8, more preferably from 5 to 7, in view of the skin irritation and the transdermal absorbability. Examples of the hydrophilic polymer include carboxyvinyl polymers (CARBOPOL 940, 941 manufactured by B.F. Goodrich Chemical Co., HIBISWAKO 104, 105, manufactured by Wako Pure Chemical Industries, Ltd., and the like), hydroxypropylcellulose (HPC-L, HPC-M manufactured by Nippon Soda Co., Ltd., and the like), polyoxyethylenepolyoxypropylene block polymer (Lutrol F68 manufactured by BASF Co., and the like). These hydrophilic polymers may be used alone or as a mixture of two or more and mixed in an amount of from 0.2 to 3% by weight, preferably, from 0.5 to 2% by weight in view of the viscosity and stickiness of the cream. Examples of the oily substance include fatty acid esters such as diisopropyl adipate, diisopropyl sebacate, diethyl sebacate, middle-length fatty acid triglycerides, middle-length fatty acid propylene glycols, isopropyl myristate, and the like; fatty acids such as stearic acid, oleic acid, myristic acid, and the like; higher alcohols such as cetanol, stearyl alcohol, cetostearyl alcohol, oleyl alcohol, behenyl alcohol, and the like; hydrocarbons such as white petrolatum, liquid paraffin, squalane, and the like; plant oils and fats such as olive oil, hohoba oil, castor oil, and the like; and other oily substances such as crotamiton, benzyl alcohol, and the like. The oily substance is mixed in an amount of preferably from 5 to 15% by weight, in view of the spreadability of cream, transdermal absorption, stickiness, shining, and instability in production of preparations (e.g., liquid separation), and the like. Examples of the surface active agent include sorbitan fatty acid esters such as sorbitan monostearate, sorbitan sesquistearate, and the like; glycerol fatty acid esters such as glyceryl monostearate, diglyceryl monooleate, and the like; polyoxyethylenesorbitan fatty acid esters such as polyoxyethylene(20)sorbitan monostearate, polyoxyethylene(20)sorbitan monooleate, and the like; polyethylene glycol fatty acid esters such as polyoxyethylene(10) monostearate, polyoxyethylene(10) monolaurate, and the like; polyoxyethylene alkyl ethers such as polyoxyethylene(9) lauryl ether, polyoxyethylene(23) cetyl ether, and the like; polyoxyethylene alkylphenyl ethers such as polyoxyethylene (10) nonylphenyl ether, polyoxyethylene(10) octylphenyl ether, and the like; and polyoxyethylene hydrogenated castor oil such as polyoxyethylene (10) hydrogenated castor oil, polyoxyethylene(60) hydrogenated castor oil, and the like. These surface active agents may be used alone or as a mixture of two or more and mixed in an amount of from 0.5 to 7% by weight preferably, from 1 to 5% by weight. Examples of the basic substance include inorganic or organic bases such as potassium hydroxide, sodium hydroxide, triethanolamine, diisopropanolamine, monoethanolamine, and the like, and organic bases are preferable from the viewpoint of the transdermal absorption. These basic substance may be mixed in an amount of from 0.01 to 5% by weight preferably from 0.1 to 2% by weight. In addition, in order to enhance the transdermal absorption of nimesulide, the absorption enhancer may be mixed in the above-described pharmaceutical preparation depending on the type of the pharmaceutical prescription. Examples of the absorption enhancer include organic bases, crotamiton, middle-length fatty acid esters, 1 -menthol, benzyl alcohol, and the like. The organic base facilitates the release of nimesulide from the base since it makes nimesulide water-soluble by forming a salt with nimesulide. Examples of the organic base include diisopropanolamine, meglumine, triethanolamine, and 1-(2-hydroxyethyl)pyrrolidine, and diisopropanolamine and 1-(2-hydroxyethyl)pyrrolidine are the most preferable. The absorption enhancer is mixed in an amount of from 0.1 to 20% by weight, preferably from 0.2 to 10% by weight, alone or as a mixture of two or more. The above-described basic substance and the organic base as an absorption enhancer act also as a pH controlling agent of the preparation. That is, when pH of the pharmaceutical preparation is too low (e.g., 3 or less), the high acidity makes skin irritation strong. When pH is too high (e.g., 9 or more), the transdermal absorbability of the medical agent is reduced, skin irritation becomes strong, and the pharmaceutical preparation colors yellow. Accordingly, the pH of the pharmaceutical preparation is controlled preferably in the range of from 4 to 8 by the amount of the above-described basic substance or the absorption enhancer to be mixed. In addition to the above-described components, animal oils and fats, waxes, hydrocarbons, antiseptics, wetting agents, and the like may be added and mixed. Examples of the animal oil and fat include beef tallow, pork tallow, horse oil, and the like. Examples of the wax include microcrystalline wax, montan wax, bees wax, and the like. Examples of the hydrocarbon include paraffin, ceresine, and the like. Examples of the antiseptic include methylparaben, propylparaben, butylparaben, and the like. Examples of the wetting agent include polyhydric alcohols such as glycerol, 1,3-butylene glycol, propylene glycol, dipropylene glycol, and the like. These additives may be the mixed in amounts generally employed for cream preparations. Examples The present invention is illustrated in greater detail with reference to the following Examples. Example 1 Component % by weight (1) Nimesulide (Particle Diameter: 5 to 20 µm) 3 (2) Carboxyvinyl Polymer 1 (3) Diisopropyl Sebacate 5 (4) Isopropyl Myristate 10 (5) Crotamiton 3 (6) Polyoxyethylene(20)sorbitan Monostearate 5 (7) Methylparaben 0.1 (8) Propylparaben 0.1 (9) Diisopropanolamine 0.5 (10) Purified Water 72.3 100.0 The components (3), (4), (5), (6), and (8) were melted by heating at 75°C. A solution which had been separately prepared by dissolving the component (7) in about 90% of the component (10) at 75°C was added, and the mixture was stirred to effect emulsification. The component (2) was gradually added at 50°C and the mixture was thoroughly stirred. Then, the component (1) was gradually added and dispersed by stirring. Then, a solution which had been prepared by dissolving the component (9) in the remaining component (10) was added, and the mixture was stirred until the mixture became homogenous to obtain an antiinflammatory cream preparation containing nimesulide. Example 2 Component % by weight (1) Nimesulide (Particle Diameter: 20 to 40 µm) 3 (2) Carboxyvinyl Polymer 1 (3) Diisopropyl Sebacate 5 (4) Isopropyl Myristate 10 (5) Crotamiton 3 (6) Polyoxyethylene(20)sorbitan Monostearate 5 (7) Methylparaben 0.1 (8) Propylparaben 0.1 (9) Diisopropanolamine 0.5 (10) Purified Water 72.3 100.0 The components (3), (4), (5), (6), and (8) were melted by heating at 75°C. A solution which had been separately prepared by dissolving the component (7) in about 90% of the component (10) at 75°C was added, and the mixture was stirred to effect emulsification. The component (2) was gradually added at 50°C and the mixture was thoroughly stirred. Then, the component (1) was gradually added and dispersed by stirring. Then, a solution which had been prepared by dissolving the component (9) in the remaining component (10) was added, and the mixture was stirred until the mixture became homogenous to obtain an antiinflammatory cream preparation containing nimesulide. Example 3 Component % by weight (1) Nimesulide (Particle Diameter: 5 to 20 µm) 3 (2) Carboxyvinyl Polymer 1 (3) Diethyl Sebacate 5 (4) Middle-length Fatty Acid Triglyceride 8 (5) Crotamiton 3 (6) Polyoxyethylene(20)sorbitan Monostearate 5 (7) Methylparaben 0.1 (8) Propylparaben 0.1 (9) 1-(2-Hydroxyethyl)pyrrolidine 0.5 (10) Purified Water 74.3 100.0 The components (3), (4), (5), (6), and (8) were melted by heating at 75°C. A solution which had been separately prepared by dissolving the component (7) in about 90% of the component (10) at 75°C was added, and the mixture was stirred to effect emulsification. The component (2) was gradually added at 50°C and the mixture was thoroughly stirred. Then, the component (1) was gradually added and dispersed by stirring. Then, a solution which had been prepared by dissolving the component (9) in the remaining component (10) was added, and the mixture was stirred until the mixture became homogenous to obtain an antiinflammatory cream preparation containing nimesulide. Example 4 Component % by weight (1) Nimesulide (Particle Diameter: 5 to 20 µm) 5 (2) Carboxyvinyl Polymer 1 (3) Diethyl Sebacate 5 (4) Middle-length Fatty Acid Triglyceride 8 (5) Crotamiton 3 (6) Polyoxyethylene(20)sorbitan Monostearate 5 (7) Methylparaben 0.1 (8) Propylparaben 0.1 (9) 1-(2-Hydroxyethyl)pyrrolidine 0.5 (10) Purified Water 72.3 100.0 The components (3), (4), (5), (6), and (8) were melted by heating at 75°C. A solution which had been separately prepared by dissolving the component (7) in about 90% of the component (10) at 75°C was added, and the mixture was stirred to effect emulsification. The component (2) was gradually added at 50°C and the mixture was thoroughly stirred. Then, the component (1) was gradually added and dispersed by stirring. Then, a solution which had been prepared by dissolving the component (9) in the remaining component (10) was added, and the mixture was stirred until the mixture became homogenous to obtain an antiinflammatory cream preparation containing nimesulide. Example 5 Component % by weight (1) Nimesulide (Particle Diameter: 0.5 to 10 µm) 3 (2) Carboxyvinyl Polymer 1 (3) Diisopropyl Adipate 5 (4) Isopropyl Myristate 10 (5) 1 -Menthol 2 (6) Polyoxyethylene(20)sorbitan Monostearate 5 (7) Methylparaben 0.1 (8) Propylparaben 0.1 (9) Diisopropanolamine 0.5 (10) Purified Water 73.3 100.0 The components (3), (4), (5), (6), and (8) were melted by heating at 75°C. A solution which had been separately prepared by dissolving the component (7) in about 90% of the component (10) at 75°C was added, and the mixture was stirred to effect emulsification. The component (2) was gradually added at 50°C and the mixture was thoroughly stirred. Then, the component (1) was gradually added and dispersed by stirring. Then, a solution which had been prepared by dissolving the component (9) in the remaining component (10) was added, and the mixture was stirred until the mixture became homogenous to obtain an antiinflammatory cream preparation containing nimesulide. Example 6 (A dispersed-type cream preparation in which the active ingredient has the particle diameter of 76 to 180 µm) Component % by weight (1) Nimesulide (Particle Diameter: 75 to 180 µm) 3 (2) Carboxyvinyl Polymer 1 (3) Isopropyl Myristate 15 (4) Polyoxyethylene (20) sorbitan Monostearate 5 (5) Methylparaben 0.1 (6) Propylparaben 0.1 (7) Propylene Glycol 3 (8) Diethanolamine 0.5 (9) Purified Water 72.3 100.0 The components (3), (4), and (6) were melted by heating at 75°C. A solution which had been separately prepared by dissolving the component (6) and (7) in about 90% of the component (9) at 75°C was added, and the mixture was stirred to effect emulsification. The component (2) was gradually added at 50°C and the mixture was thoroughly stirred. Then, the component (1) was gradually added and dispersed by stirring. Then, a solution which had been prepared by dissolving the component (8) in the remaining component (9) was added, and the mixture was stirred until the mixture became homogenous to obtain an antiinflammatory cream preparation containing nimesulide. Reference Example (A cream preparation in which the active ingredient is dissolved) Component % by weight (1) Nimesulide (Particle Diameter: 75 to 180 µm) 3 (2) Carboxyvinyl Polymer 1 (3) Isopropyl Myristate 15 (4) Polyoxyethylene(20)sorbitan Monostearate 5 (5) Methylparaben 0.1 (6) Propylparaben 0.1 (7) Propylene Glycol 3 (8) Diethanolamine 0.5 (9) Purified Water 72.3 100.0 The components (3), (4), and (6) were melted by heating at 75°C. A solution which had been separately prepared by dissolving the components (5) and (7) in about 90% of the component (9) at 75°C was added, and the mixture was stirred to effect emulsification. The component (2) was gradually added at 50°C and the mixture was thoroughly stirred to dissolve the component (2). Then, the component (1) was gradually added and mixed by stirring. Then, a solution which had been prepared by dissolving the component (8) in the remaining component (9) was added, and the mixture was stirred until the mixture became homogenous to obtain an antiinflammatory cream preparation containing nimesulide. Test Example 1: Suppression test of carrageenin-induced rat foot edema The antiinflammatory activity of the cream preparations of Examples 1, 2, 5 and 6 and Reference Example as well as a commercially available indomethacin-containing cream preparation were examined based on the suppression of carrageenin-induced rat foot edema. Test Method The test substance was applied on a right foot sole of male Wister rats each weighing 132 to 150 g, and the right foot sole was fixed by covering with wrapping film. When the drug was applied, the animal was shackled with a plastic neck shackle and put into an individual cage in order to avoid oral ingestion of the drug. After 4 hours from the application of the drug, the drug was completely removed with absorbent cotton containing slightly warm water. Immediately, a physiological saline containing 1% carrageenin (0.1 ml) was subcutaneously injected at foot sole. After 3 hours, the foot volume was measured, and the edematization ratio was calculated based on the foot volume before injection of prophlogistic substance. The test results are shown in Table 1. Sample (administered amount: 100 mg/site) Number of animals Edematization ratio (%) (after 3 hours) Control 8 77.6 Cream preparation of Example 1 8 38.9 Cream preparation of Example 2 8 35.1 Cream preparation of Example 5 8 45.6 Cream preparation of Example 6 8 64.6 Cream preparation of Reference Example 8 53.1 Commercially available indomethacin cream preparation 8 68.6 From the results in Table 1, it is clear that the pharmaceutical preparations of Examples 1, 2, 5 and 6 showed superior antiinflammatory effect in comparison with the commercially available indomethacin cream preparation, which is equal or higher even in comparison with the cream preparation of Reference Example containing nimesulide in a dissolved state. Test Example 2: Coloring test The cream preparations of the present invention and the cream preparation of the Reference Example were prepared and spread on a cotton cloth, and the degree of coloring was observed. The test results are shown in Table 2. Sample Appearance at the time of preparation Coloring of cloth Cream preparation of Example 1 Slightly yellowish white cream Almost no coloring Cream preparation of Example 2 Slightly yellowish white cream Almost no coloring Cream preparation of Reference Example Yellow cream Colored yellow As is clear from Table 2, the cloth was colored in the case of the cream preparation of Reference Example containing nimesulide in a dissolved state but the cream preparations of Examples 1 and 2 according to the present invention showed almost no coloring. Effect of the Invention The antiinflammatory agent for external use of the present invention in which nimesulide is mixed in a dispersed state has pharmacological effects equal to or higher than those of the dissolved-type preparation, has no skin irritation, is safe, and does not soil the skin and clothes since it is not colored. Accordingly, the present invention is extremely useful as an agent in the field of dermatology for treating eczema, dermatitis, and the like, and as an antiinflammatory external preparation in the field of orthosis for treating chronic articular rheumatism, osteoarthritis, shoulder joint periarthritis, peritendinitis, myalgia, and tumentia and pain after injury.

Claims: An antiinflammatory agent for external use comprising nimesulide as an active ingredient and a base component, wherein nimesulide in an amount of 0.1 to 5 % by weight is mixed in a dispersed state in a gel-like cream base comprising a hydrophilic polymer in an amount of from 0,2 to 3% by weight, an oily substance in an amount of from 2 to 20% by weight, a non ionic surface active agent in an amount of from 0.5 to 7% by weight, a basic substance in an amount of from 0.01 to 5% by weight, and water in an amount of from 50 to 90% by weight An antiinflammatory agent for external use according to claim 1, wherein said basic substance is diisopropanolamine, meglumine, triethanolamine, and/or 1-(2-hydroxyethyl)pyrrolidine. The antiinflammatory agent for external use according to claim 1, wherein nimesulide has a mean particle diameter of from 0.01 to 75 µm.

Inventors: KAWAMURA YOICHI, MASUDA KENJI, MIYATA SATORU, TANIGUCHI YASUAKI, KAWAMURA, YOICHI, MASUDA, KENJI, MIYATA, SATORU, TANIGUCHI, YASUAKI, KAWAMURA, YOICHI, HISAMITSU PHAR. CO., INC., MASUDA, KENJI, HISAMITSU PHAR. CO., INC., MIYATA, SATORU, HISAMITSU PHAR. CO., INC., TANIGUCHI, YASUAKI, HISAMITSU PHARM. CO., INC.
Applicants: HELSINN HEALTHCARE SA, HELSINN HEALTHCARE S.A.
Application year: 1995
Main classification: A61K31
IPC codes: A61K47, A61K31, A61K9